Why the study?
Does ranolazine prevent anthracycline-induced cardiotoxicity?
Does ranolazine prevent anthracycline-induced cardiotoxicity?
Answers are grounded in this paper and cite their sources.
This review hypothesizes that ranolazine, an INaL inhibitor, may protect against anthracycline-induced cardiotoxicity by interrupting a ROS-dependent vicious cycle.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Corradi et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: